To assess the efficacy and safety of dual-site aiTBS targeting the left DLPFC and left cerebellum compared to single-site aiTBS targeting only the left DLPFC in reducing suicidal ideation among adolescents with MDD, specifically focusing on the reduction in Beck Scale for Suicide Ideation (BSI) scores.
Key Findings:
Dual-site aiTBS significantly reduced suicidal ideation compared to single-site aiTBS, with statistical significance.
The intervention was well tolerated with high adherence rates, indicating feasibility.
The cerebellum's involvement in the treatment suggests a novel approach to addressing suicidal ideation in adolescents, warranting further investigation.
Interpretation:
The findings support the efficacy of dual-site aiTBS as a promising intervention for rapidly reducing suicidal thoughts in adolescents with MDD, potentially offering a new avenue for suicide prevention and highlighting the need for further research in clinical settings.
Limitations:
The study was conducted at a single site, which may limit generalizability and introduce site-specific biases.
Long-term effects of dual-site aiTBS on suicidal ideation were not assessed beyond the 1-month follow-up, leaving questions about sustainability.
Conclusion:
Dual-site aiTBS targeting both the left DLPFC and cerebellum is a feasible and effective treatment for reducing suicidal ideation in adolescents with MDD.
